Teva Pharma (TEVA) Announces New Data Supporting Safety and Efficacy Profile of AJOVY Shared at 7th European Academy of Neurology Congress

New Data Supporting the Safety and Efficacy Profile of AJOVY® (fremanezumab) Shared at 7th European Academy of Neurology Congress

Pooled analysis of fremanezumab Phase 3 studies indicates a positive cardiovascular safety profile in adult patients Further data on injection-related adverse events provides fresh guidance for healthcare professionals in optimal selection of injection sites

AMSTERDAM--(BUSINESS WIRE)-- A new analysis presented by Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) on AJOVY® (fremanezumab) injection for the preventive treatment of migraine, indicates to the European neurology community that the medicine has a positive safety profile in relation to risk of cardiovascular... More